About Insulin-like growth factor-binding protein 2
Insulin-like growth factor-binding protein 2 (IGFBP2) is a protein
from Homo sapiens identified by UniProt accession
P18065, 325 residues long.
MolForge cross-references it against 0 known binders and
550 disease associations.
Target properties
| Protein name | Insulin-like growth factor-binding protein 2 |
|---|
| UniProt accession | P18065 |
|---|
| Gene | IGFBP2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 325 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (550)
Diseases linked to this target (Open Targets).
- protein measurement · score 0.31
- neurodegenerative disease · score 0.31
- body height · score 0.29
- esophageal carcinoma · score 0.27
- cutaneous melanoma · score 0.18
- vital capacity · score 0.15
- PHF-tau measurement · score 0.14
- cortical surface area measurement · score 0.12
- lung adenocarcinoma · score 0.12
- glioblastoma multiforme · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P18065-F1 | alphafold | PREDICTED | 66.29 | — |
Amino-acid sequence (325 residues)
MLPRVGCPAL PLPPPPLLPL LLLLLGASGG GGGARAEVLF RCPPCTPERL AACGPPPVAP PAAVAAVAGG ARMPCAELVR EPGCGCCSVC ARLEGEACGV YTPRCGQGLR CYPHPGSELP LQALVMGEGT CEKRRDAEYG ASPEQVADNG DDHSEGGLVE NHVDSTMNML GGGGSAGRKP LKSGMKELAV FREKVTEQHR QMGKGGKHHL GLEEPKKLRP PPARTPCQQE LDQVLERIST MRLPDERGPL EHLYSLHIPN CDKHGLYNLK QCKMSLNGQR GECWCVNPNT GKLIQGAPTI RGDPECHLFY NEQQEARGVH TQRMQ
Explore Insulin-like growth factor-binding protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets